Linapride M 1000mg/5mg Tablet XR

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, thereby promoting glucose-dependent insulin secretion and suppressing glucagon release. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Linapride M is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components.

Caution is advised in patients with hepatic dysfunction or congestive heart failure. Regular monitoring of renal function, blood glucose, and HbA1c levels is recommended during therapy. Adverse effects may include gastrointestinal disturbances, hypoglycemia (especially when used with other antidiabetic agents), and rare cases of lactic acidosis. This combination therapy offers a synergistic approach to glycemic control by targeting multiple pathophysiological defects in type 2 diabetes.